1. Introduction {#sec1}
===============

There are two members of the rat enhancer of split- and hairy-related protein (SHARP) family, SHARP-1 (also referred to as the DEC2 and bhlhe41) and SHARP-2 (also referred to as the DEC1, Stra13, and bhlhe40). These are basic helix-loop-helix transcriptional repressors and also function as molecular clocks \[[@bib1]\]. It has been reported that SHARP-1, SHARP-2-, or double knockout mice showed delayed circadian rhythms in glucose metabolism \[[@bib2],[@bib3]\]. Both SHARP-1 and SHARP-2 form homo- and hetero-dimers and regulate transcription of their target genes via direct binding to the E box sequence (5′-CANNTG-3′) \[[@bib1]\]. These genes are ubiquitously expressed and their gene expressions are regulated in a cell type-specific manner by various extracellular stimuli such as growth factors, serum starvation, hypoxia, hormones, nutrient, cytokines, light, and infection \[[@bib1],[@bib3],[@bib4]\]. We reported that both the levels of SHARP-1 and SHARP-2 mRNAs were induced by insulin in the rat liver, primary cultured rat hepatocytes, and highly differentiated H4IIE rat hepatoma cells \[[@bib5],[@bib6]\]. Insulin represses transcription of the rat *phosphoenolpyruvate carboxykinase (PEPCK)* gene. We reported that members of the SHARP family inhibited transcription of the rat *PEPCK* gene \[[@bib6],[@bib7]\]. Accordingly, we hypothesize that members of the SHARP family are involved in lowering the blood glucose levels by insulin.

The sirtuin (SIRT) family in mammals has seven isoforms \[[@bib8]\]. These function as β-nicotinamide adenine dinucleotide (NAD^+^)-dependent protein deacetylase. SIRT1 deacetylates histones and multiple non-histone target proteins such as p53, FOXO1/3, PGC-1α, and NF-κB \[[@bib9]\]. By targeting these proteins, SIRT1 regulates numerous vital signaling pathways, including DNA repair, apoptosis, muscle and fat differentiation, neurogenesis, mitochondrial biogenesis, glucose and insulin homeostasis, hormone secretion, cell stress responses, longevity, and circadian rhythms \[[@bib9]\]. It has been reported that an increase of glucose tolerance and a decrease of the levels of blood cholesterol and insulin were observed in transgenic mice overexpressing SIRTl \[[@bib10]\]. This status is similar to that of caloric-restricted mice \[[@bib10]\]. On the other hand, SIRT1-knockout mice lost their improved exercise function and prolonged lifespan as confirmed by caloric restriction \[[@bib11]\]. These results indicate that SIRTl is a major factor in these events caused by a caloric restriction. During fasting, glucagon secreted from pancreatic α cells stimulates transcription of the gluconeogenic enzyme *PEPCK* and *glucose-6-phosphatase* genes via the cyclic AMP (cAMP)/protein kinase A signaling pathway. In contrast, after feeding, insulin secreted from pancreatic β cells represses transcription of these genes. In the fasted rat liver, SIRT1 binds to the transcriptional coactivator PGC-1α and deacetylates its lysine residues dependent on NAD^+^, thereby inducing the *PEPCK* gene expression \[[@bib12]\].

Actions of member of the SHARP family and SIRT1 in the expression of the *PEPCK* gene are reversal. Although they play an important role in regulating glucose metabolism in the liver, the molecular mechanism remains to be determined. The aim of this study was to identify a correlation between the *SHARP-1* gene expression and the *SIRT1* gene expression ([Fig. 1](#fig1){ref-type="fig"}). The findings indicated that the *SHARP-1* gene and the *SIRT1* gene negatively regulate their expression each other.Fig. 1**A correlation between SHARP-1 and SIRT1 in regulating glucose metabolism in the liver**.Fig. 1

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Dulbecco\'s modified Eagle\'s medium (DMEM), fetal bovine serum (FBS), β-nicotinamide mononucleotide (NMN), GenElute Plasmid Miniprep Kit, and rabbit anti-FLAG antibody (F7425) were purchased from Sigma-Aldrich Co. (Saint Louis, U.S.A.). Streptomycin and penicillin G were purchased from Meijiseika (Tokyo, Japan). Sirtinol was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The TRIzol reagent and horseradish peroxidase conjugate-goat anti-rabbit IgG antibody (\#G-21234) were purchased from Invitrogen (Groningen, the Netherlands). High Capacity RNA-to-cDNA Kit was purchased from Applied Biosystems Japan (Tokyo, Japan). FastStart Universal SYBR Green Master (Rox) and GenoPure Plasmid Maxi kit were purchased from Roche Diagnostics (Indianapolis, U.S.A.). The pGL4.11 and phRL-CMV plasmids, and Dual Luciferase Reporter Assay System were obtained from Promega (Madison, U.S.A.). The Bio-Rad Protein Assay was purchased from Bio-Rad Laboratories (Hercules, CA). Bullet PAGE One Precast Gel 8% was purchased from nacalai tesque (Kyoto, Japan). Polyvinylidene difluoride (PVDF) membrane and Immobilon Western chemiluminescent HRP substrate were purchased from MILLIPORE (Bedford, MA). Rabbit anti-SIRT1(D1D7) antibody (\#9475) was purchased from Cell Signaling Technology (Danvers, MA). Mouse anti-β-Actin (C4) antibody (SC-47778) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase conjugate-goat anti-mouse IgG antibody (1030--05) was purchased from SouthernBiotech (Birmingham, AL). The pCMV-Tag2 plasmid and Quik change Lightning Site-Directed Mutagenesis kit were purchased from Agilent Technology (Santa Clara, U.S.A.)

2.2. Cells and cell culture {#sec2.2}
---------------------------

Rat H4IIE hepatoma cells were a generous gift from Dr. Daryl K. Granner (Vanderbilt University, U.S.A.). HepG2 cells were purchased from the JCRB Cell Bank (Osaka, Japan). These cells were grown in DMEM supplemented with 10% FBS, 100 μg/ml streptomycin and 100 units/ml penicillin G at 37 °C in a 5% CO~2~ incubator. One million H4IIE cells were seeded in a 6-cm dish. After 24 h, the medium was replaced with serum-free DMEM and then cultured for another 24 h. At 2 h after the medium was replaced with the same medium, the cells were treated with the indicated concentrations of sirtinol or NMN for various times.

2.3. Real-time polymerase chain reactions (PCRs) {#sec2.3}
------------------------------------------------

Preparation of total RNA from various H4IIE cells, reverse transcription, and real-time PCRs were previously described \[[@bib13], [@bib14], [@bib15], [@bib16]\].

2.4. Construction of plasmids {#sec2.4}
-----------------------------

A *BamH*I/*Hind*III fragment containing the nucleotide sequences between −831 and + 1 or −809 and + 1 of the human *SIRT1* gene was synthesized by Life technologies (Carlsbad, USA). Each fragment was subcloned into the *Bgl*II/*Hind*III sites of the pGL4.11 plasmid to produce the phSIRT1/Luc-831 and phSIRT1/Luc-809, respectively. The pCMV-SHARP-1 and pZHX1/Luc-88 plasmids were previously described \[[@bib6],[@bib17]\]. The pCMV-SIRT1 plasmid which expresses SIRT1 in a mammalian cell was a generous gift from Dr. Youichi Tajima (Tokyo Metropolitan Institute of Medical Science, Tokyo).

The phSIRT1/Luc-831 plasmid was used as the template. PCR was performed in combinations of the following primers, 5′-CCGGGGATCCACCCGTAGTGTTGTGGTCTG-3′ and 5′-CCGGAAGCTTCTTCCAACTGCCTCTC-3′, 5′-CCGGGGATCCATGGGGTTTAAATCTCCCGCA-3′ and 5′-CCGGAAGCTTCTTCCAACTGCCTCTC-3′, respectively. PCR products were digested with *BamH*I/*Hind*III, then each fragment was subcloned into the *Bgl*II/*Hind*III sites of the pGL4.11 plasmid to give the phSIRT1/Luc-183 and the phSIRT1/Luc-104, respectively. Site-directed mutagenesis was carried out using the Quik change Lightning Site-Directed Mutagenesis kit. The phSIRT1/Luc-183 plasmid was used as a template for mutagenesis to obtain the phSIRT1/Luc-183 mut with a disrupted E box (CA[T]{.ul}G[C]{.ul}G) (mutated bases are underlined). PCR was performed in a combination of primers, 5′-GGGGCGGCGATGGGGCGGGTCATGCGATGGGGTTTAAATCTCCCGCA-3 and 5′-TGCGGGAGATTTAAACCCCATCGCATGACCCGCCCCATCGCCGCCCC-3'. The pSHARP-1/Luc-1500 plasmid was previously described \[[@bib18]\]. The nucleotide sequences of all inserts were confirmed.

2.5. Western blot analysis {#sec2.5}
--------------------------

H4IIE or HepG2 cells transfected with 0.5 μg or 25 ng of the pCMV-Tag or pCMV-SHARP-1, respectively. Procedures for preparation of whole cell lysates and western blot analysis were previously described \[[@bib15]\]. Briefly, whole cell lysates (20 μg) were resolved with 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a PVDF membrane for western blot analysis. The SIRT1 antibody (1:400 dilution), the FLAG antibody (1:500 dilution), and the β-actin (1:1000 dilution) were used as primary antibody. Horseradish peroxidase conjugate-goat anti-rabbit IgG antibody (1:4000 or 5000 dilution) or horseradish peroxidase conjugate-rabbit anti-mouse IgG antibody (1:4000 dilution) was employed as the second antibody. Visualization and analysis of the proteins were also previously described \[[@bib15]\].

2.6. Transient DNA transfections and luciferase reporter assays {#sec2.6}
---------------------------------------------------------------

All plasmids were prepared using the GenoPure Plasmid Maxi kit. A calcium-phosphate method was employed for transfection into H4IIE cells \[[@bib19]\]. Briefly, H4IIE cells were co-transfected with 8 μg of a reporter plasmid and 0.1 μg of the phRL-CMV plasmid. After transfection, the medium was replaced with serum-free DMEM and cells were cultured for 16 h.

Fifty thousand HepG2 cells were seeded in a 24 wells plate. Cells were transfected with 200 ng of a reporter plasmid, the indicated amount of an effector plasmid, and 0.001 ng of the phRL-CMV using the lipofection method. The total amount of plasmid was adjusted by the addition of the pCMV-Tag2 plasmid, if necessary. After 3 h, the medium was replaced with DMEM supplemented with 10% FBS and antibiotics, and cells were cultured for another 48 h.

Firefly and sea pansy luciferase assays were carried out using the Dual Luciferase Reporter Assay System. Procedures were performed according to the manufacture\'s recommended protocol. Luciferase activities were determined by a Berthold Lumat model LB 9507 (Wildbad, Germany). Firefly luciferase activities (relative light units) were normalized by sea pansy luciferase activities.

2.7. Statistical analysis {#sec2.7}
-------------------------

All experiments were carried out at least three times. Data were represented as the mean and standard error and analyzed by one-way ANOVA followed by Fisher\'s protected LSD multiple comparison test.

3. Results {#sec3}
==========

3.1. SIRT1 negatively regulates the *SHARP-1* gene expression {#sec3.1}
-------------------------------------------------------------

SIRT1 stimulates transcription of the *PEPCK* gene, while member of the SHARP family repress it \[[@bib5], [@bib6], [@bib7],[@bib12]\]. To evaluate a correlation with these gene expressions, we investigated whether SIRT1 affects expression of mRNA of the SHARP-1. Either sirtinol as a SIRT1 inhibitor or NMN as a SIRT1 activator was employed. First, H4IIE cells were treated with various concentrations of sirtinol for 2 h. The level of SHARP-1 mRNA significantly increased in a dose-dependent manner ([Fig. 2](#fig2){ref-type="fig"}A). Then, the time courses for the increase in the SHARP-1 mRNA levels at 100 μmol/l of sirtinol was analyzed. The level of SHARP-1 mRNA gradually increased, reaching a maximum level at 2 h and then decreased ([Fig. 2](#fig2){ref-type="fig"}B).Fig. 2**Effect of sirtinol or NMN on the level of SHARP-1 mRNA.** Total RNA was prepared from H4IIE cells under various conditions. The levels of SHARP-1 and 36B4 mRNAs were determined. Each column and bar represents the mean and standard error of the ratio of the levels of SHARP-1 and 36B4 mRNAs of three or four independent experiments. The value of the ratio in the absence of inhibitor or activator was set to 1. (A) H4IIE cells were treated for 2 h with the concentrations of sirtinol indicated on the bottom. (B) Cells were cultured in the absence or presence of 100 μmol/l sirtinol for the times indicated on the bottom. (C) H4IIE cells were treated for 4 h with the concentrations of NMN indicated on the bottom. (D) Cells were cultured in the absence or presence of 50 μmol/l NMN for the times indicated on the bottom. (E) Whole cell lysates were prepared from H4IIE cells treated with the concentrations of NMN indicated on the upper for 4 h. Whole cell lysates (20 μg/lane) were resolved using a 8% SDS- PAGE gel and transferred onto a PVDF membrane for western blot analysis. Rabbit anti-SIRT1 antibody (SIRT1), or mouse anti-rat β-actin antibody (β-actin) were used as primary antibody. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.Fig. 2

Next, H4IIE cells were treated with various concentrations of NMN for 4 h. The SHARP-1 mRNA level significantly decreased at 50 μmol/l of NMN ([Fig. 2](#fig2){ref-type="fig"}C). The time course analysis at 50 μmol/l of NMN revealed that the levels of SHARP-1 mRNA was down-regulated at 4 h ([Fig. 2](#fig2){ref-type="fig"}D). And the level of SIRT1 protein almost remained unchanged by NMN treatment ([Fig. 2](#fig2){ref-type="fig"}E).

These results suggest that SIRT1 negatively regulates the *SHARP-1* gene expression.

3.2. SHARP-1 specifically represses the transcriptional activity of the *SIRT1* gene {#sec3.2}
------------------------------------------------------------------------------------

Next, we determined whether SHARP-1 affects the transcriptional activity of the human *SIRT1* gene. We employed the phSIRT1/Luc-831 plasmid as a reporter plasmid in which the nucleotide sequences between −831 and + 1 of the human *SIRT1* gene were inserted into a firefly luciferase reporter plasmid. The phRL-CMV plasmid is a cytomegalovirus enhancer/promoter-driven sea pansy luciferase expression plasmid. The plasmid expressing SHARP-1 was co-transfected with the reporter and the phRL-CMV plasmids into H4IIE cells. When the SHARP-1 expression plasmid was co-transfected, the luciferase activities were dramatically decreased to 50% ([Fig. 3](#fig3){ref-type="fig"}A). We confirmed the production of SHARP-1 protein in H4IIE cells by western blot analysis using the antibody against FLAG ([Fig. 3](#fig3){ref-type="fig"}B).Fig. 3**SHARP-1 specifically represses the transcriptional activity of the human*****SIRT1*****gene.**(A) The phSIRT1/Luc-831 plasmid was used as the reporter plasmid. The pCMV-SHARP-1 was used as the expression plasmid. H4IIE cells were transiently transfected with 8 μg of a luciferase reporter plasmid, the indicated amount of an effector plasmid shown on the bottom, and 0.1 μg of the phRL-CMV using a calcium phosphate method. After transfection, cells were cultured for 16 h in the serum-free DMEM. A value of 100 was assigned to the promoter activity from reporter plasmid in the presence of the pCMV-Tag2 plasmid. (C) HepG2 cells were co-transfected with 200 ng of the phSIRT1/Luc-831 or the pZHX1/Luc-88 luciferase reporter plasmid, the indicated amount of the pCMV-SHARP-1 shown on the bottom, and 0.001 ng of the phRL-CMV using the lipofection method. Firefly luciferase activities were normalized by sea pansy luciferase activities. A value of 100 was assigned to the promoter activity from each reporter plasmid in the presence of the pCMV-Tag2 plasmid. Each column and bar represents the mean and standard error of four independent experiments. Whole cell lysates were prepared from (B) H4IIE cells transfected with 0.5 μg or (D) HepG2 cells transfected with 25 ng of the pCMV-Tag or pCMV-SHARP-1 respectively. Whole cell lysates (20 μg/lane) were resolved using a 8% SDS- PAGE gel and transferred onto a PVDF membrane for western blot analysis. Rabbit anti FLAG antibody (FLAG), or mouse anti-rat β-actin antibody (β-actin) were used as primary antibody. \*\*P \< 0.01; \*\*\*P \< 0.001.Fig. 3

Then, to confirm whether SHARP-1 specifically affects the human *SIRT1* gene promoter, we used another hepatic cell line, HepG2 cells. HepG2 cells are easier transfected with plasmids than H4IIE cells. The pZHX1/Luc-88 plasmid in which the nucleotide sequences between −88 and −1 of the mouse *zinc-fingers and homeoboxes 1 (ZHX1)* transcriptional repressor gene were inserted into the reporter plasmid was also employed as a negative control reporter plasmid. The luciferase activities of the phSIRT1/Luc-831 decreased by a co-transfection with the SHARP-1 as well as H4IIE cells ([Fig. 3](#fig3){ref-type="fig"}C). In contrast, promoter activity from the pZHX1/Luc-88 plasmid was not changed by co-transfection with these plasmids ([Fig. 3](#fig3){ref-type="fig"}C). We confirmed the production of SHARP-1 protein in HepG2 cells by western blot analysis using the antibody against FLAG ([Fig. 3](#fig3){ref-type="fig"}D).

These results indicate that SHARP-1 specifically represses the transcriptional activity of the human *SIRT1* gene.

3.3. SHARP-1 represses promoter activity of the *SIRT1* gene via an E box {#sec3.3}
-------------------------------------------------------------------------

In order to map a SHARP-1 responsive region of the *SIRT1* gene, we prepared three 5′- deletion constructs. The phSIRT1/Luc-809, the phSIRT1/Luc-183, and the phSIRT1/Luc-104 plasmids contained nucleotide sequences between −809 and + 1, −183 and + 1, and −104 and + 1 of the human *SIRT1* gene, respectively. When the SHARP-1 expression plasmid was co-transfected with these reporter plasmids, promoter activities of the phSIRT1/Luc-809 and the phSIRT1/Luc-183 were decreased ([Fig. 4](#fig4){ref-type="fig"}A). However, promoter activity of the phSIRT1/Luc-104 was not affected ([Fig. 4](#fig4){ref-type="fig"}A). In contrast, SHARP-1 had no change the promoter activity of the empty vector, the pGL4.11 plasmid ([Fig. 4](#fig4){ref-type="fig"}A).Fig. 4**SHARP-1 represses promoter activity of the human*****SIRT1*****gene via an E box.** HepG2 cells were co-transfected with 200 ng of a luciferase reporter plasmid, 100 ng of the pCMV-SHARP-1, and 0.001 ng of the phRL-CMV using the lipofection method. The reporter constructs contained (A) various length of the *SIRT1* gene promoter and no promoter or (B) a disrupted E box element. Details for determination of the luciferase activities and statistical analysis are described in [Fig. 3](#fig3){ref-type="fig"} n. s.: not significant.Fig. 4

These results indicate that the region of −183 to −105 of the *SIRT1* gene contains an important region responding to SHARP-1.

SHARP-1 binds to the E box sequence of the target genes and represses their transcription \[[@bib1]\]. In the region from −831 to +1 of the *SIRT1* gene, there are eight E box sequences, two of which are CACGTG. An CACGTG E box sequence existed in the region from −183 to −105 of the *SIRT1* gene. We then investigated whether the E box sequence is involved in a decrease of promoter activity by SHARP-1. The phSIRT1/Luc-183 was mutated in its E box sequence to produce the phSIRT1/Luc-183 mut. The inhibitory effect on promoter activity by SHARP-1 disappeared in phSIRT1/Luc-183 mut ([Fig. 4](#fig4){ref-type="fig"}B).

This result indicates that SHARP-1 represses promoter activity of the *SIRT1* gene via an E box 5′-CACGTG-3′ locating from −110 to −105 of the gene.

3.4. Effect of SIRT1 on promoter activity of the SHARP-1 gene {#sec3.4}
-------------------------------------------------------------

SIRT1 acts as a protein deacetylase \[[@bib8]\]. It is known that deacetylation of histone proteins decreases transcriptional activities. We determined whether SIRT1 affects promoter activity of the rat *SHARP-1* gene. A SIRT1 expression plasmid was co-transfected with several reporter plasmids into HepG2 cells. The nucleotide sequences between −1500 and −1 of the rat *SHARP-1* gene was inserted into a luciferase reporter plasmid to obtain the pSHARP-1/Luc-1500 plasmid. When the reporter plasmid was co-transfected with the SIRT1 expression plasmid, SIRT1 had no effect on the promoter activity within the investigated condition ([Fig. 5](#fig5){ref-type="fig"}A). We confirmed the production of SIRT1 protein in HepG2 cells by western blot analysis using the antibody against SIRT1 ([Fig. 5](#fig5){ref-type="fig"}B).Fig. 5**Effect of SIRT1 on the promoter activity of the rat*****SHARP-1*****gene.** (A) HepG2 cells were co-transfected with 200 ng of the pSHARP-1/Luc-1500 luciferase reporter plasmid, the indicated amount of the pCMV-SIRT1 shown on the bottom, and 0.001 ng of the phRL-CMV using the lipofection method. Details for determination of the luciferase activities and statistical analysis are described in [Fig. 3](#fig3){ref-type="fig"} n. s.: not significant. (B) Whole cell lysates were prepared from HepG2 cells transfected with 25 ng of pCMV-Tag or pCMV-SIRT1, respectively. Whole cell lysates (20 μg/lane) were resolved using a 8% SDS- PAGE gel and transferred onto a PVDF membrane for western blot analysis. Rabbit anti-rat SIRT1 antibody (SIRT1), or mouse anti-rat β-actin antibody (β-actin) were used as primary antibody.Fig. 5

This result suggests that a SIRT1-responsive element does not exist in the nucleotide sequences between −1500 and −1 of the rat *SHARP-1* gene.

4. Discussion {#sec4}
=============

A correlation of expressions between the *SHARP-1 gene* and *SIRT1* gene was examined. Expression of the *SHARP-1* gene was elevated by a SIRT1 inhibitor and down-regulated by a SIRT1 activator ([Fig. 2](#fig2){ref-type="fig"}). Promoter activity of the *SIRT1* gene was specifically inhibited by SHARP-1 ([Fig. 3](#fig3){ref-type="fig"}). Further analysis using 5′- deleted or mutated constructs showed that a CACGTG E box sequence of the *SIRT1* gene promoter was required for the inhibitory effect of SHARP-1 ([Fig. 4](#fig4){ref-type="fig"}). Therefore, these findings suggest that expression between the *SHARP-1* gene and the *SIRT1* gene was a negative correlation.

We have found that the *SIRT1* gene is a novel target gene of SHARP-1. There are no reports involving in transcription factors directly acting on the promoter region of the *SIRT1* gene. SHARP-1 acted on a CACGTG E box existing from −110 to −105 in the promoter region. It has been reported that SHARP-1 has strong affinity with CACGTG but not CACCTG and CAGCTG \[[@bib20]\]. In addition, SHARP-1 repress transcription of the clock gene, *Per 1* through a binding to a CACGTG sequence in the promoter region \[[@bib21]\]. Therefore, it seems to be true that SHARP-1 binds to the CACGTG sequence of the *SIRT1* gene.

Promoter activity from the phSIRT1/Luc-183 mut plasmid which is mutated in the E box sequence was higher than that from the phSIRT1/Luc-104 plasmid but lower than that from the phSIRT1/Luc-183 plasmid (data not shown). This suggests that this E box sequence is necessary for the basal level of the *SIRT1* gene expression and that other positive elements should exist in the region of −183 to −105.

We elucidated that SIRT1 may inhibit the *SHARP-1* gene expression ([Fig. 2](#fig2){ref-type="fig"}). We then examined whether SIRT1 effect the promoter activity of the rat *SHARP-1* gene using a luciferase reporter gene assay. The nucleotide sequences between −1501 and −1 of the rat *SHARP-1* gene contain some transcriptional regulatory elements essential for basal expression and regulation by hypoxia \[[@bib22]\]. However, this region did not respond to the SIRT1 expression ([Fig. 5](#fig5){ref-type="fig"}). Therefore, the response elements should exist in a region other than between −1501 and −1 of the rat *SHARP-1* gene.

In this study, our results showed that SIRT1 repressed the *SHARP-1* gene expression, SHARP-1 inhibited promoter activity of the *SIRT1* gene, and SIRT1 and SHARP-1 inhibited the expressions of their genes each other. These findings suggest that SIRT1 and SHARP-1 regulate hepatic glucose metabolism by mutually exclusive gene expressions. This interrelationship of expressions between these genes in rat hepatoma cells should provide new insight into molecular mechanism by which gene expression in glucose homeostasis is regulated in the liver.

Further studies will be needed to clarify whether SHARP-1 actually binds to the *SIRT1* gene promoter via a protein-DNA interaction, which a cis-acting element of the rat *SHARP-1* gene respond to SIRT1, and which signal transduction pathways are involved in expression of both genes.
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